Cargando…
1335. Safety and Pharmacokinetic Profile of PC786, a Novel Inhibitor of Respiratory Syncytial Virus L-protein Polymerase, in a Single and Multiple-Ascending Dose Study in Healthy Volunteer and Mild Asthmatics
BACKGROUND: RSV is the most common cause of bronchiolitis in infants and is responsible for severe respiratory infections in the elderly and immunocompromised populations. RSV replicates in the columnar epithelial cells of the proximal and distal airways which are accessible to inhaled therapies. PC...
Autores principales: | Cass, Lindsey, Davis, Amanda, Murray, Alison, Woodward, Kathy, Ito, Kazuhiro, Strong, Pete, Rapeport, Garth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253606/ http://dx.doi.org/10.1093/ofid/ofy210.1167 |
Ejemplares similares
-
Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study
por: DeVincenzo, John, et al.
Publicado: (2020) -
Late therapeutic intervention with a respiratory syncytial virus L‐protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium
por: Brookes, Daniel W, et al.
Publicado: (2018) -
Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor
por: Coates, Matthew, et al.
Publicado: (2017) -
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
por: Cass, Lindsey, et al.
Publicado: (2020) -
In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice
por: Kimura, Genki, et al.
Publicado: (2017)